Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

Slides:

Advertisements

Similar presentations

Jiliang Xia, Hongwei Xu, Xiaoyan Zhang, Chantal Allamargot, Kristen L

Advertisements

Elevated FOXC2 Expression Promotes Invasion of HCC Cell Lines and is Associated with Poor Prognosis in Hepatocellular Carcinoma Cell Physiol Biochem 2017;44:99–109.

Volume 18, Issue 12, Pages (December 2016)

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

Antitumor Efficacy of the Anti-Interleukin-6 (IL-6) Antibody Siltuximab in Mouse Xenograft Models of Lung Cancer Lanxi Song, MS, Matthew A. Smith, PhD,

Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition.

Fig. 3. LTB4 exhibits concentration-dependent effects on HLEC lymphangiogenesis and survival. LTB4 exhibits concentration-dependent effects on HLEC lymphangiogenesis.

Fig. 5 Maraba induces antitumor T cell immunity.

In vivo prophylactic and therapeutic efficacy of C12G6 in mice

In vivo responses of AMLMLL to ATRi.

Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.

Fig. 8. In vivo suppression of MM by CMLD

Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.

Maraba treatment sensitizes 4T1 tumors to immune checkpoint blockade

Intravenous delivery of reovirus to primary and secondary brain tumors

Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Fig. 1. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. Paclitaxel delays tumor growth and promotes.

Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.

Fig. 4 Expression of cleaved caspase 3, PD-L1, and PD-1 in HGGs after reovirus treatment. Expression of cleaved caspase 3, PD-L1, and PD-1 in HGGs after.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Fig. 5 Combination intravenous reovirus and checkpoint inhibition in an orthotopic syngeneic brain tumor model. Combination intravenous reovirus and checkpoint.

Fig. 6. Apoptotic MSCs exert in vivo immunosuppression in a TH2-type inflammation model in the absence of cytotoxic cells. Apoptotic MSCs exert in vivo.

Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.

Fig. 7 BRD0705 impairs colony formation in AML cell lines and patient cells and shows in vivo efficacy in multiple AML mouse models. BRD0705 impairs colony.

Fig. 4 DMF enhances VSVΔ51 therapeutic efficacy in syngeneic and xenograft tumor models. DMF enhances VSVΔ51 therapeutic efficacy in syngeneic and xenograft.

Fig. 7. KIF11 informs patient prognosis, and targeting improves survival in a preclinical model. KIF11 informs patient prognosis, and targeting improves.

Fig. 5 Local gel scaffold for T cell memory response.

Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.

Fig. 4. Loss of DLK expression is neuroprotective in the SOD1G93A mouse model of ALS. Loss of DLK expression is neuroprotective in the SOD1G93A mouse model.

Fig. 8 SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and in vivo. SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and.

Comparison of therapeutic efficacies of C12G6 and other bnAbs in mice

Combination of IAP Antagonists and TNF-α-Armed Oncolytic Viruses Induce Tumor Vascular Shutdown and Tumor Regression Shawn T. Beug, Stephanie J. Pichette,

Stroke induces atheroprogression via the RAGE-signaling pathway

Fig. 6. pKL cells revert hyperglycemia in NOD mice in vivo.

Fig. 7. mRIPO therapy restricts tumor growth and produces antigen-specific antitumor immunity. mRIPO therapy restricts tumor growth and produces antigen-specific.

Fig. 3. TKI sensitivity assessed by the MANO method.

Fig. 4. Efficacy of C12G6 compared with and in combination with oseltamivir in mice. Efficacy of C12G6 compared with and in combination with oseltamivir.

Fig. 6 Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing mice. Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing.

Fig. 3 Agonists of innate immunity are effective only when released locally from the hydrogel. Agonists of innate immunity are effective only when released.

Fig. 5. Prophylactic and therapeutic efficacy of C12G6 in ferrets.

Fig. 3 CSF1 is expressed in human melanoma.

Fig. 4. Local application of FR provides prolonged protection against Gq-dependent airway constriction in normal and OVA-sensitized mice in vivo. Local.

Fig. 5 ALRN-6924 shows robust antileukemic activity in primary AML cells and in vivo. ALRN-6924 shows robust antileukemic activity in primary AML cells.

Fig. 1 LB100 and LB102 specifically inhibit PP2A phosphatase activity and the growth of BCR-ABL+ cells. LB100 and LB102 specifically inhibit PP2A phosphatase.

Therapeutic activity of gal‐encapsulated cytotoxic drugs on tumor xenografts Therapeutic activity of gal‐encapsulated cytotoxic drugs on tumor xenografts.

Fig. 5 Metarrestin treatment induces nucleolar structure changes.

Correlation of reovirus RNA/protein with proliferating tumor cells

ONC201 activates the ISR. ONC201 activates the ISR. (A) Western blotting analysis for ATF4, CHOP, ATF3, and TRB3 on lysates from HCT116 cells cultured.

Fig. 1. Iontophoretic devices used for the delivery of cytotoxic agents to solid tumors. Iontophoretic devices used for the delivery of cytotoxic agents.

Genetic EGFR ablation in K-RAS–mutated lung AC reduces tumor growth

Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal tumors. Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal.

Fig. 4 Rational therapeutic modulation of the tumor microenvironment sensitizes tumors to ICB. Rational therapeutic modulation of the tumor microenvironment.

Fig. 2 Inflammatory pathways with STAT1 as a key regulator are enriched in ICB responsive tumors in mouse models and patients. Inflammatory pathways with.

In vivo assessment of synergistic activity of MV-CEA and RT in a U87 s

E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective breast tumors. E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective.

PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant p53 in vivo. PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant.

Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ) in vivo. Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ)

Five-day exposure to decitabine (DAC) sensitizes cells to doxorubicin (Doxo). Five-day exposure to decitabine (DAC) sensitizes cells to doxorubicin (Doxo).

Effect of CDV on human SF7796 xenografts in vivo.

In vivo prophylactic and therapeutic efficacy of C12G6 in mice

Fig. 1. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. Paclitaxel delays tumor growth and promotes.

MYC expression is correlated with dasatinib sensitivity in cancer cell lines and in vivo. MYC expression is correlated with dasatinib sensitivity in cancer.

Fig. 5 In vivo autologous self-targeting efficacy of DR-KO tumor cells co-engineered with a secretable DRL and a suicide system. In vivo autologous self-targeting.

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

Fig. 6 KHK-A–mediated p62 S28 phosphorylation promotes hepatocellular tumorigenesis and is associated with clinical aggressiveness of human HCC. KHK-A–mediated.

In vivo effect of KIN-193 on PTEN-deficient tumors.

Presentation transcript:

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. (A) Timeline of the experimental setup for (B) and (C). (B) Hep3B xenografts were treated with vehicle, M1 virus (5 × 105 PFUs, intravenously), EerI (2 mg/kg, intraperitoneally), or a combination. Data are mean tumor volume ± SD (eight mice per group). ***P < 0.001 for M1-EerI combination versus single agents. (C) Huh 7 xenografts were treated with vehicle, M1 virus (5 × 105 PFUs, intravenously), EerI (2 mg/kg, intraperitoneally), or a combination. Data are mean tumor volume ± SD (eight mice per group). ***P < 0.001 for M1-EerI combination versus single agents. (D) Timeline of the experimental setup for (E). (E) Kaplan-Meier survival curve of mice bearing Hep3B tumors treated with vehicle, M1 virus (1 × 106 PFUs, intravenously), EerI (2 mg/kg, intraperitoneally), or a combination. CTL, n = 7; EerI, n = 7; M1, n = 8; M1 + EerI, n = 8. ***P < 0.001, log-rank with Holm-Sidak multiple comparisons. (F) Representative images of livers from each group in (E) at day 15. Dashed blue lines represent tumor areas. (G) Timeline of experimental setup for (H). (H) Kaplan-Meier survival curves of immunocompetent mice bearing Hepa1-6 tumors treated with vehicle, M1 virus (1 × 106 PFUs, intravenously), CB-5083 (25 mg/kg, orally), or a combination. CTL, n = 6; CB-5083, n = 5; M1, n = 6; M1 + CB-5083, n = 6. ***P < 0.001, log-rank with Holm-Sidak multiple comparisons. (I) Representative images of livers from each group in (H) at day 15. Dashed blue lines represent tumor areas. (J) Tumor tissues from (F) were evaluated through immunohistochemistry for Ki-67 (a marker of proliferation), IRE1α (a marker of the UPR pathway), p-JNK (a marker of ER stress–induced apoptosis), cleaved caspase-3, and E1 (structural protein of M1 virus). N, nontumor area; T, tumor area. Scale bar, 50 μm. (K) HCC tissues from five patients were treated with vehicle, EerI (10 μM), M1 (2 × 106 PFUs), or a combination for 96 hours, and cell viability was assessed. (L) Amounts of VCP protein in five patients. P, patient. Quantification (indicated by the numbers at the top) was performed using ImageJ software. (M) Correlation of cytotoxicity and relative VCP expression. r is the Pearson correlation coefficient. Haipeng Zhang et al., Sci Transl Med 2017;9:eaam7996 Published by AAAS